Clinical Trial Update: A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• LEO 138559

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED